Mechanism of acid hypersecretion post curative gastrinoma resection

Digestive Diseases and Sciences

Volumn 56, Issue 1, 2011, Pages 139-154

  Ojeaburu, Jeremiah V ^a   Ito, Tetsuhide ^b   Crafa, Pellegrino ^c   Bordi, Cesare ^c   Jensen, Robert T ^a  

^a NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES   (United States)

^b KYUSHU UNIVERSITY   (Japan)

^c UNIVERSITY OF PARMA   (Italy)

Author keywords

Acid secretion; ECL cells; Gastrinoma; Proton pump inhibitors; Zollinger Ellison syndrome

Indexed keywords

CHROMOGRANIN A; GASTRIN; MEDRONATE TECHNETIUM TC 99M; OMEPRAZOLE; PROTON PUMP INHIBITOR; SECRETIN;

ADULT; ARTICLE; BASAL ACID OUTPUT; CLINICAL ARTICLE; CLINICAL ASSESSMENT; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; CORRELATION ANALYSIS; DISEASE MARKER; FEMALE; GASTRECTOMY; GASTRIN BLOOD LEVEL; GASTRINOMA; GASTROESOPHAGEAL REFLUX; GASTROINTESTINAL ENDOSCOPY; HUMAN; HYPERGASTRINEMIA; MALE; MAXIMAL ACID OUTPUT; NUCLEAR MAGNETIC RESONANCE IMAGING; POSTOPERATIVE PERIOD; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROVOCATION TEST; RISK FACTOR; STOMACH ACID SECRETION; STOMACH BIOPSY; TUMOR LOCALIZATION; URINALYSIS; ZOLLINGER ELLISON SYNDROME;

ENTEROCHROMAFFIN CELLS; FEMALE; FOLLOW-UP STUDIES; GASTRIC ACID; GASTRINOMA; GASTRINS; HUMANS; HYPERPLASIA; MALE; MIDDLE AGED; PANCREATIC NEOPLASMS; PARIETAL CELLS, GASTRIC; POSTOPERATIVE PERIOD; PREVALENCE; PROSPECTIVE STUDIES; ZOLLINGER-ELLISON SYNDROME;

EID: 79151468825     PISSN: 01632116     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10620-010-1234-1     Document Type: Article

References (73)

1. RT Jensen B Niederle E Mitry JK Ramage, et al. 2006 Gastrinoma (duodenal and pancreatic) Neuroendocrinology 84 173 182 1:CAS:528:DC%2BD2sXhvFSmtrY%3D 10.1159/000098009 17312377
2. P Roy DJ Venzon KM Feigenbaum PD Koviack, et al. 2001 Gastric secretion in Zollinger-Ellison syndrome: correlation with clinical expression, tumor extent and role in diagnosis-A prospective NIH study of 235 patients and review of the literature in 984 cases Medicine (Baltimore) 80 189 222 1:STN:280:DC%2BD3MzhsFChsg%3D%3D 10.1097/00005792-200105000-00005
3. JA Norton RT Jensen 2004 Resolved and unresolved controversies in the surgical management of patients with Zollinger-Ellison syndrome Ann Surg 240 757 773 10.1097/01.sla.0000143252.02142.3e 15492556
4. Maton PN, Dayal Y. Clinical implications of hypergastrinemia. In: Zakim D, Dannenberg AJ, eds. Peptic Ulcer Disease and Other Acid-Related Disorders. Armonk, NY: Academic Research Associates; 1991:213-246.
5. PL Peghini B Annibale C Azzoni M Milione, et al. 2002 Effect of chronic hypergastrinemia on human enterochromaffin-like cells: insights from patients with sporadic gastrinomas Gastroenterology 123 68 85 10.1053/gast.2002.34231 12105835
6. PN Maton EE Lack MJ Collen MJ Cornelius, et al. 1990 The effect of Zollinger-Ellison syndrome and omeprazole therapy on gastric oxyntic endocrine cells Gastroenterology 99 943 950 1:STN:280:DyaK3czmsl2gtA%3D%3D 1697548
7. W Creutzfeldt 1988 The achlorhydria-carcinoid sequence: role of gastrin Digestion 39 61 79 1:CAS:528:DyaL1cXitF2ltr8%3D 3044896
8. RT Jensen 2002 Involvement of cholecystokinin/gastrin-related peptides and their receptors in clinical gastrointestinal disorders Pharmacol Toxicol 91 333 350 1:CAS:528:DC%2BD3sXis12qtw%3D%3D 10.1034/j.1600-0773.2002.910611.x 12688377
9. Jensen RT. Gastrinoma as a model for prolonged hypergastrinemia in man. In: Walsh JH, ed. Gastrin. New York, NY: Raven Press Publishing Co; 1993:373-393.
10. Richter JE. Gastroesophageal reflux disease. In: Yamada T, Alpers DH, Kalloo AN, Kaplowitz N, Owyang C, Powell DW, eds. Textbook of Gastroenterology. Oxford, UK: Blackwell; 2009:772-801.
11. RT Jensen 2006 Consequences of long-term proton pump blockade: highlighting insights from studies of patients with gastrinomas Basic Clin Pharmacol Toxicol 98 4 19 1:CAS:528:DC%2BD28XhsFegsLk%3D 10.1111/j.1742-7843. 2006.pto-378.x 16433886
12. JB Jansen EC Klinkenberg-Knol SG Meuwissen JW De Bruijne, et al. 1990 Effect of long-term treatment with omeprazole on serum gastrin and serum group A and C pepsinogens in patients with reflux esophagitis Gastroenterology 99 621 628 1:STN:280:DyaK3czjslWgsQ%3D%3D 2199288
13. MJ Berna KM Hoffmann J Serrano F Gibril RT Jensen 2006 Serum gastrin in Zollinger-Ellison syndrome: I. Prospective study of fasting serum gastrin in 309 patients from the National Institutes of Health and comparison with 2229 cases from the literature Medicine (Baltimore) 85 295 330 1:CAS:528:DC%2BD28Xht1SmtrrE 10.1097/01.md.0000236956.74128.76
14. EC Klinkenberg-Knol HPM Festen JBMJ Jansen CBHW Lamers, et al. 1994 Long-term treatment with omeprazole for refractory reflux esophagitis: efficacy and safety Ann Intern Med 121 161 167 1:STN:280:DyaK2c3ovVeqtA%3D%3D 8017742
15. EC Klinkenberg-Knol F Nelis J Dent P Snel, et al. 2000 Long-term omeprazole treatment in resistant gastroesophageal reflux disease: efficacy, safety and influence on gastric mucosa Gastroenterology 118 661 669 1:CAS:528:DC%2BD3cXis1ens74%3D 10.1016/S0016-5085(00)70135-1 10734017
16. E Solcia C Bordi W Creutzfeldt Y Dayal, et al. 1988 Histopathological classification of nonantral gastric endocrine growths in man Digestion 41 185 200 1:STN:280:DyaL1M3htFKhtw%3D%3D 10.1159/000199786 3072229
17. G Delle Fave G Capurso M Milione F Panzuto 2005 Endocrine tumours of the stomach Best Pract Res Clin Gastroenterol 19 659 673 1:CAS:528: DC%2BD2MXhtFKntrbP 10.1016/j.bpg.2005.05.002 16253892
18. B Wangberg O Nilsson E Theodorsson IM Modlin, et al. 1995 Are enterochromaffinlike cell tumours reversible? An experimental study on gastric carcinoids induced in Mastomys by histamine2-receptor blockade Regul Pept 56 19 33 1:STN:280:DyaK2M3ovVCktQ%3D%3D 10.1016/0167-0115(95)00123-S 7770630
19. D Gillen KE McColl 2001 Problems related to acid rebound and tachyphylaxis Best Pract Res Clin Gastroenterol 15 487 495 1:CAS:528: DC%2BD38XhvV2gug%3D%3D 10.1053/bega.2001.0190 11403541
20. NG Hunfeld WP Geus EJ Kuipers 2007 Systematic review: rebound acid hypersecretion after therapy with proton pump inhibitors Aliment Pharmacol Ther 25 39 46 1:CAS:528:DC%2BD2sXht12qurw%3D 10.1111/j.1365-2036.2006.03171.x 17229219
21. Waldum HL, Qvigstad G, Fossmark R, Kleveland PM, Sandvik AK. Rebound acid hypersecretion from a physiological, pathophysiological and clinical viewpoint. Scand J Gastroenterol 2009;45:389-394.
22. R Fossmark G Johnsen E Johanessen HL Waldum 2005 Rebound acid hypersecretion after long-term inhibition of gastric acid secretion Aliment Pharmacol Ther 21 149 154 1:STN:280:DC%2BD2M%2FltFKmsQ%3D%3D 10.1111/j.1365-2036.2004.02271.x 15679764
23. C Reimer B Sondergaard L Hilsted P Bytzer 2009 Proton-pump inhibitor therapy induces acid-related symptoms in healthy volunteers after withdrawal of therapy Gastroenterology 137 80 87 1:CAS:528:DC%2BD1MXovFOgsb8%3D 10.1053/j.gastro.2009.03.058 19362552
24. MJ Berna B Annibale M Marignani TV Luong, et al. 2008 A prospective study of gastric carcinoids and enterochromaffin-like cells changes in multiple endocrine neoplasia type 1 and Zollinger-Ellison syndrome: identification of risk factors J Clin Endocrinol Metabol 93 1582 1591 1:CAS:528: DC%2BD1cXlvFWhu7Y%3D 10.1210/jc.2007-2279
25. JA Norton HR Alexander DL Fraker DJ Venzon RT Jensen 2004 Does the use of routine duodenotomy (DUODX) affect rate of cure, development of liver metastases or survival in patients with Zollinger-Ellison syndrome (ZES)? Ann Surg 239 617 626 10.1097/01.sla.0000124290.05524.5e 15082965
26. JR Pisegna JA Norton GG Slimak DC Metz, et al. 1992 Effects of curative resection on gastric secretory function and antisecretory drug requirement in the Zollinger-Ellison syndrome Gastroenterology 102 767 778 1:STN:280: DyaK387msFSjsQ%3D%3D 1537514
27. VA Fishbeyn JA Norton RV Benya JR Pisegna, et al. 1993 Assessment and prediction of long-term cure in patients with Zollinger-Ellison syndrome: the best approach Ann Intern Med 119 199 206 1:STN:280:DyaK3szhtFOkuw%3D%3D 8323088
28. MJ Berna KM Hoffmann SH Long J Serrano, et al. 2006 Serum gastrin in Zollinger-Ellison syndrome: II. Prospective study of gastrin provocative testing in 293 patients from the National Institutes of Health and comparison with 537 cases from the literature. Evaluation of diagnostic criteria, proposal of new criteria, and correlations with clinical and tumoral features Medicine (Baltimore) 85 331 364 1:CAS:528:DC%2BD28Xht1SmtrrF 10.1097/MD.0b013e31802b518c
29. C Bordi C Azzoni G Ferraro VD Corleto, et al. 2000 Sampling strategies for analysis of enterochromaffin-like cell changes in Zollinger-Ellison syndrome Am J Clin Pathol 114 419 425 1:STN:280:DC%2BD3cvkt1Ohuw%3D%3D 10989643
30. SU Goebel J Serrano F Yu F Gibril, et al. 1999 Prospective study of the value of serum chromogranin A or serum gastrin levels in assessment of the presence, extent, or growth of gastrinomas Cancer 85 1470 1483 1:STN:280:DyaK1M3gvVakuw%3D%3D 10.1002/(SICI)1097-0142(19990401)85:7<1470: AID-CNCR7>3.0.CO;2-S 10193936
31. K Borch M Stridsberg P Burman JF Rehfeld 1997 Basal chromogranin A and gastrin concentrations in circulation correlate to endocrine cell proliferation in type-A gastritis Scand J Gastroenterol 32 198 202 1:STN:280: DyaK2s3jvFOqsQ%3D%3D 10.3109/00365529709000194 9085454
32. S Sanduleanu M Stridsberg D Jonkers W Hameeteman, et al. 1999 Serum gastrin and chromogranin A during medium-and long-term acid suppressive therapy: a case-control study Aliment Pharmacol Ther 13 145 153 1:CAS:528: DyaK1MXitVeksbk%3D 10.1046/j.1365-2036.1999.00466.x 10102943
33. G Granerus 1968 Effects of oral histamine, histidine and diet on urinary excretion of histamine, methylhistamine and 1-methyl-4-imidazoleacetic acid in man Scand J Clin Lab Invest 104 49 58 1:STN:280:DyaF1M%2FptlCrsA%3D%3D
34. S Bashir F Gibril J Ojeaburu B Asgharian, et al. 2002 Prospective study of the ability of histamine, serotonin or chromogranin A levels to identify gastric carcinoids in patients with gastrinomas Aliment Pharmacol Ther 16 1367 1382 1:CAS:528:DC%2BD38XntVCjs70%3D 10.1046/j.1365-2036.2002.01249.x 12144588
35. JA Norton DL Fraker HR Alexander DJ Venzon, et al. 1999 Surgery to cure the Zollinger-Ellison syndrome N Engl J Med 341 635 644 1:STN:280: DyaK1MzotlKnsQ%3D%3D 10.1056/NEJM199908263410902 10460814
36. AG Krudy JL Doppman RT Jensen JA Norton, et al. 1984 Localization of islet cell tumors by dynamic CT: comparison with plain CT, arteriography, sonography and venous sampling Am J Roentgenol 143 585 589 1:STN:280: DyaL2c3nslehsw%3D%3D
37. F Gibril JC Reynolds CC Chen F Yu, et al. 1999 Specificity of somatostatin receptor scintigraphy: a prospective study and the effects of false positive localizations on management in patients with gastrinomas J Nucl Med 40 539 553 1:STN:280:DyaK1M3isV2itQ%3D%3D 10210211
38. F Gibril JL Doppman JC Reynolds CC Chen, et al. 1998 Bone metastases in patients with gastrinomas: a prospective study of bone scanning, somatostatin receptor scanning, and MRI in their detection, their frequency, location and effect of their detection on management J Clin Oncol 16 1040 1053 1:STN:280:DyaK1c7mslKitg%3D%3D 9508189
39. JL Doppman DL Miller R Chang PN Maton, et al. 1990 Gastrinomas: localization by means of selective intraarterial injection of secretin Radiology 174 25 29 1:STN:280:DyaK3c%2FpvFOqug%3D%3D 2294556
40. HR Alexander DL Fraker JA Norton DL Barlett, et al. 1998 Prospective study of somatostatin receptor scintigraphy and its effect on operative outcome in patients with Zollinger-Ellison syndrome Ann Surg 228 228 238 1:STN:280:DyaK1czns1Citg%3D%3D 10.1097/00000658-199808000-00013 9712569
41. RT Jensen 1998 Management of the Zollinger-Ellison syndrome in patients with multiple endocrine neoplasia type 1 J Intern Med 243 477 488 1:CAS:528:DyaK1cXks1Wkur4%3D 10.1046/j.1365-2796.1998.00281.x 9681846
42. JA Norton HR Alexander DL Fraker DJ Venzon, et al. 2001 Comparison of surgical results in patients with advanced and limited disease with multiple endocrine neoplasia type 1 and Zollinger-Ellison syndrome Ann Surg 234 495 506 1:STN:280:DC%2BD3MrmslOmtA%3D%3D 10.1097/00000658-200110000-00009 11573043
43. F Gibril M Schumann A Pace RT Jensen 2004 Multiple endocrine neoplasia type 1 and Zollinger-Ellison syndrome. A prospective study of 107 cases and comparison with 1009 patients from the literature Medicine 83 43 83 10.1097/01.md.0000112297.72510.32 14747767
44. H Frucht JA Norton JF London R Vinayek, et al. 1990 Detection of duodenal gastrinomas by operative endoscopic transillumination: a prospective study Gastroenterology 99 1622 1627 1:STN:280:DyaK3M%2Fjt1Orug%3D%3D 2227278
45. RV Benya DC Metz DJ Venzon VA Fishbeyn, et al. 1994 Zollinger-Ellison syndrome can be the initial endocrine manifestation in patients with multiple endocrine neoplasia-type 1 Am J Med 97 436 444 1:STN:280:DyaK2M%2FmvVSgug%3D%3D 10.1016/0002-9343(94)90323-9 7977432
46. MR Aprile C Azzoni F Gibril RT Jensen C Bordi 2000 Intramucosal cysts in the gastric body of patients with Zollinger-Ellison syndrome Hum Pathol 31 140 148 1:STN:280:DC%2BD3c7kvVSlsQ%3D%3D 10.1016/S0046-8177(00)80213-0 10685627
47. P Roy DJ Venzon H Shojamanesh A Abou-Saif, et al. 2000 Zollinger-Ellison syndrome: clinical presentation in 261 patients Medicine 79 379 411 1:STN:280:DC%2BD3M%2FntFKisg%3D%3D 10.1097/00005792-200011000-00004 11144036
48. DC Metz JR Pisegna VA Fishbeyn RV Benya, et al. 1992 Currently used doses of omeprazole in Zollinger-Ellison syndrome are too high Gastroenterology 103 1498 1508 1:STN:280:DyaK3s%2FltFSltw%3D%3D 1426868
49. MJ Collen RT Jensen 1994 Idiopathic gastric acid hypersecretion: comparison with Zollinger-Ellison syndrome Dig Dis Sci 39 1434 1440 1:STN:280:DyaK2c3pvVCgug%3D%3D 10.1007/BF02088045 8026253
50. 12 levels in patients with Zollinger-Ellison syndrome Am J Med 104 422 430 1:CAS:528:DyaK1cXktVSjtbc%3D 10.1016/S0002-9343(98)00087-4 9626024
51. D Gillen AA Wirz JE Ardill KE McColl 1999 Rebound hypersecretion after omeprazole and its relation to on-treatment acid suppression and Helicobacter pylori status Gastroenterology 116 239 247 1:CAS:528:DyaK1MXht1CgsLk%3D 10.1016/S0016-5085(99)70118-6 9922302
52. DC Metz HC Weber M Orbuch DB Strader, et al. 1995 Helicobacter pylori infection: a reversible cause of hypergastrinemia and hyperchlorhydria which can mimic Zollinger-Ellison syndrome Dig Dis Sci 40 153 159 1:STN:280: DyaK2M7itFSrtw%3D%3D 10.1007/BF02063959 7821103
53. HC Weber DJ Venzon RT Jensen DC Metz 1997 Studies on the interrelation between Zollinger-Ellison syndrome, Helicobacter pylori and proton pump inhibitor therapy Gastroenterology 112 84 91 1:STN:280:DyaK2s7jt12rtQ%3D%3D 10.1016/S0016-5085(97)70222-1 8978346
54. R Lamberts W Creutzfeldt HG Struber G Brunner E Solcia 1993 Long-term omeprazole therapy in peptic ulcer disease: gastrin, endocrine cell growth, and gastritis Gastroenterology 104 1356 1370 1:STN:280:DyaK3s3ks1WitQ%3D%3D 8482449
55. L Ekman E Hansson N Havu E Carlsson C Lundberg 1985 Toxicological studies on omeprazole Scand J Gastroenterol 20 Suppl 108 53 69
56. HL Waldum E Brenna AK Sandvik 2002 Long-term safety of proton pump inhibitors: risks of gastric neoplasia and infections Expert Opin Drug Saf 1 29 38 1:CAS:528:DC%2BD38Xlsl2nurk%3D 10.1517/14740338.1.1.29 12904157
57. AK Sandvik E Brenna HL Waldum 1997 Review article: the pharmacological inhibition of gastric acid secretion-tolerance and rebound Aliment Pharmacol Ther 11 1013 1018 1:CAS:528:DyaK1cXhsVKhtw%3D%3D 10.1046/j.1365-2036.1997.00257. x 9663823
58. KE McColl D Gillen 2009 Evidence that proton-pump inhibitor therapy induces the symptoms it is used to treat Gastroenterology 137 20 22 10.1053/j.gastro.2009.05.015 19482105
59. H Larsson E Carlsson B Ryberg J Fryklund B Wallmark 1988 Rat parietal cell function after prolonged inhibition of gastric acid secretion Am J Physiol 254 G33 G39 1:CAS:528:DyaL1cXktlWrurc%3D 2827515
60. KJ LePard JR Mohammed RL Stephens Jr 1997 Gastric ECL-cell hyperplasia produces enhanced basal and stimulated gastric acid output but not gastric erosion formation in the rat Gen Pharmacol 28 415 420 1:CAS:528: DyaK2sXltVSlsbY%3D 9068983
61. H Larsson E Carlsson H Mattsson L Lundell, et al. 1986 Plasma gastrin and gastric enterochromaffin-like cell activation and proliferation. Studies with omeprazole and ranitidine in intact and antrectomized rats Gastroenterology 90 391 399 1:CAS:528:DyaL28XhsVamtb0%3D 3510144
62. A Nishida A Kobayashi-Uchida S Akuzawa Y Takinami, et al. 1995 Gastrin receptor antagonist YM022 prevents hypersecretion after long-term acid suppression Am J Physiol 269 G699 G705 1:CAS:528:DyaK2MXpslOhtr0%3D 7491961
63. E Carlsson H Larsson H Mattsson B Ryberg G Sundell 1986 Pharmacology and toxicology of omeprazole-with special reference to the effects on the gastric mucosa Scand J Gastroenterol (Suppl) 118 31 38 1:STN:280:DyaL283mtFKgsg%3D%3D 10.3109/00365528609090884
64. WM Weinstein AF Ippoliti SW Lee LJ Weber DA Lieberman 1996 Acid hypersecretion, parietal cell hyperplasia, and endoscopic changes after withdrawal of long term high dose omeprazole therapy: a prospective study Gastroenterology 110 4 A294
65. H Larsson E Carlsson R Hakanson H Mattsson, et al. 1988 Time-course of development and reversal of gastric endocrine cell hyperplasia after inhibition of acid secretion Gastroenterology 95 1477 1486 1:CAS:528:DyaL1MXhvVemtA%3D%3D 3181674
66. Y Tielemans D Chen F Sundler R Hakanson G Willems 1992 Reversibility of the cell kinetic changes induced by omeprazole in the rat oxyntic mucosa. An autoradiographic study using tritiated thymidine Scand J Gastroenterol 27 155 160 1:CAS:528:DyaK38XhvVOrsLw%3D 10.3109/00365529209165437 1561530
67. WY Chey TM Chang HJ Park KY Lee, et al. 1984 Non-gastrin secretagogue in ulcerogenic tumors of the pancreas Ann Intern Med 101 7 13 1:STN:280: DyaL2c3ivFKmtw%3D%3D 6145381
68. WY Chey TM Chang KY Lee G Sun, et al. 1989 Ulcerogenic tumor syndrome of the pancreas associated with a nongastric acid secretogogue Ann Surg 210 139 149 1:STN:280:DyaL1MzjsVCisA%3D%3D 10.1097/00000658-198908000-00002 2757418
69. Jensen RT. Treatment of pancreatic Zollinger-Ellison syndrome and other gastric hypersecretory states. In: Wolfe MM, ed. Therapy of Digestive Disorders. A Companion to Sleisenger and Fordtran's Gastrointestinal and Liver Diseases. Philadelphia: W.B. Saunders Co; 2000:169-187.
70. RT Jensen MJ Berna MD Bingham JA Norton 2008 Inherited pancreatic endocrine tumor syndromes: advances in molecular pathogenesis, diagnosis, management and controversies Cancer 113 7 suppl 1807 1843 10.1002/cncr.23648 18798544
71. PM Kirkpatrick Jr BI Hirschowitz 1980 Duodenal ulcer with unexplained marked basal gastric acid hypersecretion Gastroenterology 79 4 10 7380221
72. Jensen RT, Gardner JD. Gastrinoma. In: Go VLW, DiMagno EP, Gardner JD, Lebenthal E, Reber HA, Scheele GA, eds. The Pancreas: Biology, Pathobiology and Disease. New York: Raven Press Publishing Co; 1993:931-978.
73. 2-receptor antagonist: comparison with cimetidine and ranitidine in the treatment of Zollinger-Ellison syndrome Gastroenterology 88 1026 1033 1:STN:280:DyaL2M7ivVaqtw%3D%3D 2857672